** Shares of Telix Pharmaceuticals Ltd TLX.AX , which
specialises in using radiology to treat cancer, climb as much as
4.8% to an all-time high of A$7.86
** Co says its marketing authorisation application
submission in Europe for registering TLX's investigational
product Illuccix has progressed to the final stage of regulatory
assessment urn:newsml:reuters.com:*:nASX92WvQl
** Telix expects a decision by no later than March 23, 2022
** Telix's lead product Illuccix, being developed for
prostate cancer imaging, has been approved by the Australian
Therapeutic Goods Administration and accepted for filing by the
U.S. Food and Drug Administration urn:newsml:reuters.com:*:nL4N2RT06R
** More than 554,600 shares change hands, compared with the
30-day average volume of ~428,300 shares
** Stock up 98.4% this year, as of last close, compared with
an 11.8% increase in the ASX All Ordinaries Index .AORD
(Reporting by Roushni Nair in Bangalore)
((Roushni.Nair@thomsonreuters.com))